Non small cell lung cancer pathophysiology

Revision as of 20:47, 6 January 2019 by Trushatank (talk | contribs)
Jump to navigation Jump to search

Non Small Cell Lung Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non Small Cell Lung Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Approach

Stage I
Stage II
Stage III
Stage IV
Metastatic Cancer

Medical Therapy

Chemotherapy
Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non small cell lung cancer pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non small cell lung cancer pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non small cell lung cancer pathophysiology

CDC on Non small cell lung cancer pathophysiology

Non small cell lung cancer pathophysiology in the news

Blogs on Non small cell lung cancer pathophysiology

Directions to Hospitals Treating Non small cell carcinoma of the lung

Risk calculators and risk factors for Non small cell lung cancer pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2],Maria Fernanda Villarreal, M.D. [3]

Overview

Non-small cell lung cancer arises from the epithelial cells of the bronchioles and alveoli, which are normally involved in the protection of the airways. Non-small cell lung cancer is an invasive and rapidly growing cancer which may metastasize to different organs of the body. Genes involved in the pathogenesis of non-small cell lung cancer include EGFR, KRAS, HER2, BRAF, and ALK. Findings on gross pathology depends on the histological subtypes of non-small cell lung cancer. On microscopic histopathological analysis non-small cell lung cancer usually demonstrates large cells with abundant cytoplasm and no stippled chromatin.

Pathogenesis

The pathogenesis of non-small cell lung cancer depends on the type of histological subtype of lung cancer.[1]

  • Non-small cell lung cancer arises from the epithelial cells of the bronchioles and alveoli, which are normally involved in the protection of the airways.
  • The genetic pathogenesis of non-small cell lung cancer is due to the amplification of oncogenes and inactivation of tumor suppressor genes.
  • Non-small cell lung cancer is an invasive and rapidly growing cancer which may metastasize to different organs of the body.

Pathogenesis according to histopathological subtypes:

Genetics

Development of non-small cell lung cancer is the result of multiple genetic mutations. Genetic mutations also play an important role in the treatment selection for non small cell lung cancer.[2]

  • The table below describes the genes involved in the pathogenesis of non small cell lung cancer.
Genes Presence in non small cell-lung cancers
EGFR
  • EGFR mutations are present in approximately 10% to 15% of all non-small cell lung cancers
KRAS
  • Mutations are present in approximately 30% of pulmonary adenocarcinomas
  • Mutations are present in approximately 5% of pulmonary squamous cell carcinomas
  • Associated with carcinomas with mucinous histology
ALK
  • Mutations are present in approximately 5% of all non-small cell lung cancers
HER2
  • Mutations are present in approximately 4% of adenocarcinomas
BRAF
  • Mutations are present in less than 2% of adenocarcinomas
ROS-1
  • Mutations are present in less than 2% of adenocarcinomas

Associated Conditions

  • Other conditions associated with non-small cell lung cancer, include:
  • Genetic conditions
  • Li–Fraumeni syndrome[3]
  • Infections

Gross Pathology

On gross pathology, findings will depend on the histological subtype of non-small cell lung cancer.

  • Lung adenocarcinoma gross pathology findings, include:[6]
  • Spherical tumor with well-defined borders
  • Homogeneous gray-white cut surface
  • Involvement of the thoracic wall
  • Usually found in the peripheral lung
  • Large cell lung cancer gross pathology findings, include:[6]
  • Well-defined borders
  • Resemblance to gross findings in adenocarcinoma
  • No signs of anthracosis
  • Involvement of the thoracic wall
  • Squamous cell lung cancer gross pathology findings, include:[6]
  • Lung mass
  • Usually centrally located
  • Associated with a large airway
  • Usually have a central cavitation

Microscopic Pathology

On microscopic pathology, findings will depend on the histological type of non-small cell lung cancer.[6]

  • Lung adenocarcinoma microscopic pathology findings, include:
  • Nuclear atypia
  • Eccentrically placed nuclei
  • Abundant cytoplasm with mucin vacuoles
  • Often conspicuous nucleoli
  • Lack of intercellular bridges.
  • Different patterns, include: acinar, lepidic, micropapillary, papillary, and solid.
  • Large cell lung cancer microscopic pathology findings, include:
  • Large polygonal cells and anaplastic cells
  • No squamous or glandular differentiation
  • Moderately abundant cytoplasm
  • Vesicular nuclei, prominent nucleoli
  • Squamous cell lung cancer microscopic pathology findings include:
  • Central nucleus
  • Dense appearing cytoplasm, usually eosinophilic
  • Small nucleolus
  • Intercellular bridges (classic feature)

On immunohistochemistry, the findings depend on the histological type of non-small cell lung cancer.[2][6]

  • Common immunohistochemistry markers used for non-small cell carcinoma subtyping, include:
  • TTF-1 for adenocarcinoma
  • p63 and high-molecular-weight keratins for squamous cell carcinoma
  • Lack of staining with neuroendocrine markers (chromogranin A, synaptophysin, and CD56)

References

  1. Miller YE (2005). "Pathogenesis of lung cancer: 100 year report". Am. J. Respir. Cell Mol. Biol. 33 (3): 216–23. doi:10.1165/rcmb.2005-0158OE. PMC 2715312. PMID 16107574.
  2. 2.0 2.1 Capelozzi VL (2009). "Role of immunohistochemistry in the diagnosis of lung cancer". J Bras Pneumol. 35 (4): 375–82. PMID 19466276.
  3. Caron, Olivier; Frebourg, Thierry; Benusiglio, Patrick R.; Foulon, Stéphanie; Brugières, Laurence (2017). "Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum". JAMA Oncology. 3 (12): 1736. doi:10.1001/jamaoncol.2017.1358. ISSN 2374-2437.
  4. Liang H, Pan Z, Cai X, Wang W, Guo C, He J, Chen Y, Liu Z, Wang B, He J, Liang W (June 2018). "The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer". Transl Lung Cancer Res. 7 (3): 397–403. doi:10.21037/tlcr.2018.03.16. PMC 6037964. PMID 30050777.
  5. Skowroński M, Iwanik K, Halicka A, Barinow-Wojewódzki A (2015). "Squamous cell lung cancer in a male with pulmonary tuberculosis". Pneumonol Alergol Pol. 83 (4): 298–302. doi:10.5603/PiAP.2015.0049. PMID 26166791.
  6. 6.0 6.1 6.2 6.3 6.4 Non small cell lung cancer. Libre Pathology. http://librepathology.org/wiki/Non-small_cell_lung_carcinoma Accessed on February 22, 2016


Template:WikiDoc Sources